Ascendis Pharma A/S (NASDAQ:ASND) Director Purchases $95,120.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime purchased 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded down $4.39 during trading on Wednesday, reaching $235.26. The stock had a trading volume of 353,256 shares, compared to its average volume of 686,936. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The business has a fifty day moving average price of $233.31 and a 200-day moving average price of $222.54. The stock has a market cap of $14.68 billion, a PE ratio of 27.13 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $156.56 and a 1-year high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 11.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Perceptive Advisors LLC acquired a new position in Ascendis Pharma A/S during the second quarter worth $166,367,000. Wellington Management Group LLP raised its position in Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after purchasing an additional 880,836 shares during the period. Principal Financial Group Inc. raised its position in Ascendis Pharma A/S by 2,722.9% in the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock valued at $157,791,000 after purchasing an additional 765,561 shares during the period. Vestal Point Capital LP raised its position in Ascendis Pharma A/S by 200.0% in the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after purchasing an additional 400,000 shares during the period. Finally, Spyglass Capital Management LLC purchased a new stake in Ascendis Pharma A/S in the third quarter valued at $77,267,000.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ASND. Wolfe Research reaffirmed an “outperform” rating and issued a $260.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Barclays lifted their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Royal Bank Of Canada boosted their price objective on Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Morgan Stanley reissued an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. Finally, Stifel Nicolaus set a $332.00 price objective on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $295.39.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.